Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2016 pp 265–271Cite as

Antianämika

  • Chapter

  • 2086 Accesses

Zusammenfassung

Der größte Teil der Verordnungen von Antianämika entfällt weiterhin auf Eisenpräparate mit einem steigenden Anteil von parenteralen Präparaten. Danach folgen Epoetinpräparate und Folsäure mit jeweils deutlich geringeren Verordnungsvolumina.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Albaramki J, Hodson EM, Craig JC, Webster AC (2012): Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev.

    Google Scholar 

  • 2012. Jan 18; 1: CD007857

    Google Scholar 

  • Auerbach M, Ballard H (2010): Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program: 338–347

    Google Scholar 

  • Baker WF, Bick RL (1999): Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost 25: 387–406

    Google Scholar 

  • Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-

    Google Scholar 

  • Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A (2009): Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373: 1532–1542

    Google Scholar 

  • Camaschella C (2015): Iron-deficiency anemia. N Engl J Med 372:1832–1843

    Google Scholar 

  • Cantor AG, Bougatsos C, Dana T, Blazina I, McDonagh M (2015): Routine iron supplementation and screening for iron deficiency anemia in pregnancy: a systematic review

    Google Scholar 

  • for the U.S. Preventive Services Task Force. Ann Intern Med 162: 566–576

    Google Scholar 

  • Curran MP, McCormack PL (2008): Methoxy polyethylene glycol-epeoetin beta: a review of ist use in the management of anaemia associated with chronic kidney disease. Drugs 68: 1139–1156

    Google Scholar 

  • Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Mcdougall IC et al. (2006): Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med

    Google Scholar 

  • 355. : 2071–2084

    Google Scholar 

  • Dührsen U (2002): Gibt es Indikationen für Erythropoetin in der Onkologie? Dtsch Ärztebl 99: A3470-A3475

    Google Scholar 

  • European Medicines Agency (2008): Questions and answers on epoetins and risk of tumor growth and blood clots in the vein. Internet: www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500015145.pdf

  • Fishbane S (2003): Safety in iron management. Am J Kidney Dis 41 (5 Suppl): 18–26

    Google Scholar 

  • Fishbane S, Mittal SK, Maesaka JK (1999): Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney Int 55: 67–70

    Google Scholar 

  • Food and Drug Administration (2007): Information for Healthcare Professionals November 8, 2007. Erythropoesis stimulating agents (ESA). Internet: www.fda.gov/cder/drug/InfoSheets/HCP/RHE200711HCP.htm

  • Hermann W, Obeid R (2011): Die obligatorische Folsäurefortifikation von Nahrungsmitteln. Ein in Deutschland kontrovers diskutiertes Thema. Dtsch Ärztebl 108: 249–254

    Google Scholar 

  • Hörl WH, Vanrenterghem Y (2005): Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. NephrolDialTransplant 20, Suppl.3: iii25–32

    Google Scholar 

  • Ibbotson T, Goa KL (2001): Darbepoetin alfa. Drugs 61: 2097–2104

    Google Scholar 

  • Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG et al. (1998): Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med

    Google Scholar 

  • 339. : 578–583

    Google Scholar 

  • Kiss JE, Brambilla D, Glynn SA, Mast AE, Spencer BR, Stone M, Kleinman SH, Cable RG; National Heart, Lung, and Blood Institute (NHLBI) Recipient Epidemiology and Donor

    Google Scholar 

  • Evaluation Study–III (REDS-III) (2015): Oral iron supplementation after blood donation: a randomized clinical trial. JAMA 313: 575–583

    Google Scholar 

  • Koletzko B, Pietrzik K (2004): Gesundheitliche Bedeutung der Folsäurezufuhr. Dtsch Ärztebl 101: A 1670–1681

    Google Scholar 

  • Lee TW, Kolber MR, Fedorak RN, van Zanten SV (2012):Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis 6: 267–275

    Google Scholar 

  • Marsh WA, Rascati KL (1999): Meta-analyses of the effectiveness of erythropoetin for end-stage renal disease and cancer. Clin Ther 21: 1443–1455

    Google Scholar 

  • Martí-Carvajal AJ, Solà I, Lathyris (2015): Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2015 Jan 15;1:CD006612.

    Google Scholar 

  • Meerpohl JJ, Schell LK, Rücker G, Motschall E, Fleeman N, Niemeyer CM, Bassler D (2014): Deferasirox for managing transfusional iron overload in people with sickle cell disease. Cochrane Database Syst Rev. 2014 May 27; 5: CD007477

    Google Scholar 

  • Nielsen P, Kongi R, Buggisch P, Fischer R (2005): Bioavailability of oral iron drugs as judged by a 59Fe-whole-body counting technique in patients with iron deficiency anaemia. Therapeutic efficacy of iron(II)-glycine sulfate. Arzneimittelforschung 55: 376–381

    Google Scholar 

  • Röhrig G, Doehner W, Schaefer RM, Schulz RJ (2012): Anämie und Eisenmangel in der Geriatrie. Prävalenz, Diagnostik und neue Therapieoptionen. Z Gerontol Geriatr 45:

    Google Scholar 

  • 191. –196

    Google Scholar 

  • Santiago P (2012): Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. ScientificWorldJournal 2012: 846824. doi: 10.1100/2012/846824.

    Google Scholar 

  • Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S et al. (2006): Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085–2098

    Google Scholar 

  • Steffensen GK, Stergaard O (2011): Administration of the same dose of epoetin-beta intravenously subcutaneously to patients with renal anaemia. Scand J Urol Nephrol 45:

    Google Scholar 

  • 461. –469

    Google Scholar 

  • Thomas L, Thomas C, Heimpel H (2005): Neue Parameter zur Diagnostik von Eisenmangelzuständen. Dtsch Ärztebl 102: A 580–586

    Google Scholar 

  • Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J (2012): Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012 Dec 12; 12: CD003407

    Google Scholar 

  • Wald NJ (2004): Folic acid and the prevention of neural-tube defects. N Engl J Med 350: 101–103

    Google Scholar 

  • Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B (2000): The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin ß: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 15: 2014–2019.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Höferstraße 15, 68199, Mannheim

    Dr. med. Klaus Mengel

Authors
  1. Dr. med. Klaus Mengel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Mengel, K. (2016). Antianämika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2016. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50351-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50351-5_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50350-8

  • Online ISBN: 978-3-662-50351-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation